Zydus receives final approval for Ethacrynate Sodium for Injection

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Ethacrynate Sodium for Injection USP, 50 mg /vial. The drug is used to decrease the swelling (edema) caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer etc. and will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Powered by Capital Market - Live News